- Home
- IMAB vs ASMB Comparison
IMAB vs ASMB Comparison
Compare IMAB & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ASMB
- Stock Information
- Founded
- IMAB 2014
- ASMB 2005
- Country
- IMAB United States
- ASMB United States
- Employees
- IMAB N/A
- ASMB N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ASMB Health Care
- Exchange
- IMAB Nasdaq
- ASMB Nasdaq
- Market Cap
- IMAB 73.9M
- ASMB 76.9M
- IPO Year
- IMAB 2020
- ASMB 2010
- Fundamental
- Price
- IMAB $0.89
- ASMB $12.41
- Analyst Decision
- IMAB Strong Buy
- ASMB Strong Buy
- Analyst Count
- IMAB 2
- ASMB 3
- Target Price
- IMAB $5.50
- ASMB $33.00
- AVG Volume (30 Days)
- IMAB 220.3K
- ASMB 26.6K
- Earning Date
- IMAB 04-03-2025
- ASMB 05-12-2025
- Dividend Yield
- IMAB N/A
- ASMB N/A
- EPS Growth
- IMAB N/A
- ASMB N/A
- EPS
- IMAB N/A
- ASMB N/A
- Revenue
- IMAB N/A
- ASMB $28,520,000.00
- Revenue This Year
- IMAB N/A
- ASMB $10.82
- Revenue Next Year
- IMAB N/A
- ASMB N/A
- P/E Ratio
- IMAB N/A
- ASMB N/A
- Revenue Growth
- IMAB N/A
- ASMB 298.16
- 52 Week Low
- IMAB $0.60
- ASMB $7.75
- 52 Week High
- IMAB $2.00
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- IMAB 53.91
- ASMB 59.56
- Support Level
- IMAB $0.81
- ASMB $9.82
- Resistance Level
- IMAB $0.97
- ASMB $14.80
- Average True Range (ATR)
- IMAB 0.06
- ASMB 0.71
- MACD
- IMAB 0.01
- ASMB 0.34
- Stochastic Oscillator
- IMAB 54.94
- ASMB 53.32
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.